Developer docs
API playgroundTry for free, no card

Search company profiles

AliveCor

Full company profile

uuid00004y5

Namestring
AliveCor
Legal namestring
AliveCor, Inc.
Websiteurl
alivecor.com
Company typeenum
Private
Founded yearint
2010
Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersMountain View, United States
HQ citystring
Mountain View
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
AI ECG analysis, cardiac monitoring devices, digital cardiology platform, heart health software, remote cardiac diagnostics
Industry3 codes
1Cardiac Monitoring (ECG/Holter/Event/Patch, Loop Recorders)
CodeHLAHACABPrimaryYes
2Cardiology Telemedicine Platforms
CodeHLALAGABPrimaryNo
3Cardiometabolic RPM & Chronic Disease Management (diabetes, hypertension, CHF, obesity)
CodeHLALAFAAPrimaryNo
NAICS code2 codes
  • Electromedical and Electrotherapeutic Apparatus Manufacturing334510
  • Instrument Manufacturing for Measuring and Testing Electricity and Electrical Signals334515
SIC code1 code
  • Electromedical & Electrotherapeutic Apparatus3845
Product category
Cardiac Diagnostic Devices and AI ECG Platform
Cost components5 values
Technology or R&D, Supply Chain, Personnel, Marketing or Sales, Operations
GTM typeB2B and B2C
B2B and B2C
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 9 records shown
1Kardia 12L
Description

AI-powered handheld 12-lead ECG system with single-cable, five-electrode design for healthcare professionals.

alivecor.com
+8 more records
Core offering1 text field

AliveCor develops and sells AI-powered ECG hardware devices (consumer KardiaMobile line and clinical Kardia 12L) paired with FDA-cleared deep neural network algorithms (Kardia AI V2, KAI 12L, Corvair) that interpret cardiac data. The company also operates enterprise software (KardiaPro), a virtual Center of Excellence cardiac care service (KardiaComplete), a consumer subscription (KardiaCare Plus), and an API/SDK that enables OEMs to embed its ECG AI into third-party devices and applications.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

AliveCor offers a platform-plus-modules architecture for AI-powered cardiac care, spanning consumer, clinical, and OEM segments. The core platform is the Kardia App paired with Kardia AI (including Kardia AI V2, KAI 12L, and Corvair algorithms) and the AliveCorCloud, which together interpret ECG signals and serve as the foundation for the broader product line. Consumer hardware modules include KardiaMobile (single-lead), KardiaMobile Card, KardiaMobile 6L, and the KardiaMobile 6L Max (with the KardiaAlert feature), all of which feed ECGs into the Kardia App. Clinical modules include the Kardia 12L 12-lead ECG system and the K1000 (InstantQT) point-of-care ECG, while the KardiaStation module supports in-clinic ECG workflows. Enterprise modules include KardiaPro (clinician platform for population-level ECG insights) and KardiaComplete Virtual Center of Excellence, which orchestrates end-to-end remote cardiac care delivery. The consumer-facing KardiaCare Plus subscription wraps these capabilities for at-home users. Finally, the API & SDK Solutions module enables OEM partners to embed AliveCor's FDA-cleared ECG AI into their own devices and applications.

Product and service12 records
1Kardia 12L
CategoryClinical ECG System
Description

AI-assisted 12-lead ECG system for healthcare professionals. It is the first AI-powered 12-lead personal/clinical ECG platform, FDA-cleared in June 2024, CE-Marked in April 2026, and expanded into India (2025) and Vietnam (2026).

2KardiaMobile 6L Max
CategoryConsumer ECG Hardware
Description

Enhanced personal 6-lead ECG device for consumer at-home cardiac monitoring, capturing six leads of cardiac data and pairing with the Kardia app for AI-interpreted results.

3KardiaMobile 6L
CategoryConsumer ECG Hardware
Description

Personal 6-lead ECG device for consumer use that records medical-grade six-lead ECGs and transmits them to the Kardia app for AI-based interpretation.

4KardiaMobile
CategoryConsumer ECG Hardware
Description

Personal single-lead ECG device for consumer at-home cardiac monitoring, paired with the Kardia app for AI interpretation.

5KardiaMobile Card
CategoryConsumer ECG Hardware
Description

Card-format personal single-lead ECG device sold to consumers for portable at-home cardiac monitoring via the Kardia app.

6K1000 (InstantQT)
7Kardia App
CategoryConsumer Mobile Application
Description

Companion mobile application that captures, displays, and analyzes ECGs from Kardia hardware devices, provides AI interpretations, integrates with Apple Health and Google Fit, and includes the AskKardia AI assistant.

8KardiaPro
CategoryEnterprise Clinician Platform
Description

Enterprise platform for healthcare providers offering real-time heart rhythm analysis, population-level ECG insights, and clinician workflow integration.

9KardiaStation
CategoryClinical Point-of-Care Software
Description

Point-of-care ECG software for clinical settings, enabling in-clinic ECG capture and AI interpretation within healthcare provider workflows.

10KardiaComplete (Virtual Center of Excellence)
CategoryVirtual Cardiac Care Service
Description

End-to-end remote cardiac care service that combines Kardia devices, AI interpretation, and clinician review to deliver a virtual Center of Excellence for cardiac monitoring and care, sold to payers, employers, and consultants on a PEPM basis.

11KardiaCare Plus
CategoryConsumer Subscription Service
Description

Subscription-based heart health membership for Kardia device users, providing expanded cardiac reporting, expert reviews, and access to KardiaComplete services.

12API & SDK Solutions
CategoryDeveloper API/SDK Platform
Description

Developer-facing API and SDK offering that allows OEM partners and third-party developers to securely pull, analyze, and display ECG results using AliveCor's FDA-cleared AI algorithms, embed ECG technology into their own applications and devices, and leverage the 250M+ ECG database.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeEmerging player
Description

Early commercial-stage company developing a credit-card-sized 3D ECG device for at-home detection of heart attacks, with FDA-cleared synthesis software. Comparable emerging player in compact AI-ECG hardware and remote cardiac diagnostics.

TypeDirect peer
Description

AI-powered digital stethoscope and cardiac auscultation/ECG platform with FDA-cleared algorithms and an enterprise provider channel. Closely comparable to AliveCor on AI-ECG technology, clinical-grade hardware, and provider/payer sales motion.

TypeBroad incumbent
Description

Global medtech incumbent with a broad cardiac monitoring portfolio (including wearable ECG and inpatient telemetry) and AI-enabled cardiology analytics. Comparable to AliveCor at the clinical/enterprise tier where it competes for hospital and health system cardiac monitoring budgets.

TypeDirect peer
Description

Consumer health hardware maker offering ScanWatch and other devices with on-wrist ECG and cardiac monitoring integrated into a consumer health app. Directly comparable to AliveCor's KardiaMobile line in consumer-grade personal ECG hardware and consumer subscription model.

TypeBroad incumbent
Description

Lead investor in AliveCor's Series F and a global medtech incumbent with cardiac diagnostics, patient monitoring, and AI imaging. A channel partner and investor, but also a broad incumbent whose cardiology portfolio overlaps AliveCor's clinical footprint at health systems.

TypeDirect peer
Description

Public digital health company (Zio long-term continuous monitoring patch) offering AI-interpreted ambulatory cardiac monitoring with FDA-cleared algorithms. Directly comparable to AliveCor in AI-ECG interpretation, clinical cardiology customers, and reimbursement-driven go-to-market.

TypeBroad incumbent
Description

Acquired by Boston Scientific, Preventice offers BodyGuardian remote cardiac monitoring (MCOT) with AI-assisted arrhythmia detection. Comparable to AliveCor in remote cardiac monitoring services and enterprise/payer GTM.

TypeBroad incumbent
Description

Apple Watch ships a built-in single-lead ECG feature integrated with iOS/Apple Health, the largest direct consumer ECG distribution channel. A broad incumbent comparable to AliveCor on consumer ECG experience and a key antagonist in the recent AliveCor antitrust dispute.

TypeBroad incumbent
Description

Acquired by Hillrom (now Baxter), Bardy's CAM patch is a single-patient-use ambulatory ECG monitor with AI analysis. Comparable to AliveCor in patch/ambulatory AI-ECG and is now part of a large medtech portfolio competing for the same clinical accounts.

TypeOthers
Description

Investor and commercial partner in AliveCor (Series C and Series E participant) and a global leader in consumer and clinical cardiovascular monitoring (blood pressure, ECG). Comparable as a strategic ecosystem participant and channel partner, not a direct AI-ECG competitor.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Ideal customer profile6 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
Yes

Docs URL, Description

Integration2 records

Each record includes

Title, Type, Description, Source

AI capability8 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles14 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries4 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance5 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds8 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors12 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

AliveCor

Cardiac Diagnostic Devices and AI ECG Platformalivecor.com

AliveCor firmographics

Firmographics
Name
AliveCor
Legal name
AliveCor, Inc.
Website
https://alivecor.com
Company type
Private
Founded year
2010
Operating status
Operating
Headcount range
51–100 employees
Ownership category
akta.pro rank

AliveCor industry classification

Industry
Product category
Cardiac Diagnostic Devices and AI ECG Platform
NAICS
Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Instrument Manufacturing for Measuring and Testing Electricity and Electrical Signals (334515)
SIC
Electromedical & Electrotherapeutic Apparatus (3845)
akta.pro primary industry
Cardiac Monitoring (ECG/Holter/Event/Patch, Loop Recorders) (HLAHACAB)
akta.pro secondary industries
Cardiology Telemedicine Platforms (HLALAGAB), Cardiometabolic RPM & Chronic Disease Management (diabetes, hypertension, CHF, obesity) (HLALAFAA)

Keywords

  • AI ECG analysis
  • Cardiac monitoring devices
  • Digital cardiology platform
  • Heart health software
  • Remote cardiac diagnostics

Where AliveCor is headquartered

Location

Headquarters

HQ city
Mountain View
HQ country
United States
HQ region
North America

Markets served

AliveCor business model

Business model
GTM type
B2B and B2C
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Supply Chain, Personnel, Marketing or Sales, Operations

AliveCor product offering

Product offering

Core offering

AliveCor develops and sells AI-powered ECG hardware devices (consumer KardiaMobile line and clinical Kardia 12L) paired with FDA-cleared deep neural network algorithms (Kardia AI V2, KAI 12L, Corvair) that interpret cardiac data. The company also operates enterprise software (KardiaPro), a virtual Center of Excellence cardiac care service (KardiaComplete), a consumer subscription (KardiaCare Plus), and an API/SDK that enables OEMs to embed its ECG AI into third-party devices and applications.

Product overview

AliveCor offers a platform-plus-modules architecture for AI-powered cardiac care, spanning consumer, clinical, and OEM segments. The core platform is the Kardia App paired with Kardia AI (including Kardia AI V2, KAI 12L, and Corvair algorithms) and the AliveCorCloud, which together interpret ECG signals and serve as the foundation for the broader product line. Consumer hardware modules include KardiaMobile (single-lead), KardiaMobile Card, KardiaMobile 6L, and the KardiaMobile 6L Max (with the KardiaAlert feature), all of which feed ECGs into the Kardia App. Clinical modules include the Kardia 12L 12-lead ECG system and the K1000 (InstantQT) point-of-care ECG, while the KardiaStation module supports in-clinic ECG workflows. Enterprise modules include KardiaPro (clinician platform for population-level ECG insights) and KardiaComplete Virtual Center of Excellence, which orchestrates end-to-end remote cardiac care delivery. The consumer-facing KardiaCare Plus subscription wraps these capabilities for at-home users. Finally, the API & SDK Solutions module enables OEM partners to embed AliveCor's FDA-cleared ECG AI into their own devices and applications.

Differentiator

Problem solved

Functional benefit

Brands

  • Kardia 12L: AI-powered handheld 12-lead ECG system with single-cable, five-electrode design for healthcare professionals.
  • KardiaMobile 6L
  • KardiaMobile
  • KardiaMobile Card
  • KardiaPro
  • KardiaStation
  • KardiaComplete
  • KardiaCare Plus
  • K1000 (InstantQT)

Products and services

  • Kardia 12L AI-assisted 12-lead ECG system for healthcare professionals. It is the first AI-powered 12-lead personal/clinical ECG platform, FDA-cleared in June 2024, CE-Marked in April 2026, and expanded into India (2025) and Vietnam (2026).
  • KardiaMobile 6L Max Enhanced personal 6-lead ECG device for consumer at-home cardiac monitoring, capturing six leads of cardiac data and pairing with the Kardia app for AI-interpreted results.
  • KardiaMobile 6L Personal 6-lead ECG device for consumer use that records medical-grade six-lead ECGs and transmits them to the Kardia app for AI-based interpretation.
  • KardiaMobile Personal single-lead ECG device for consumer at-home cardiac monitoring, paired with the Kardia app for AI interpretation.
  • KardiaMobile Card Card-format personal single-lead ECG device sold to consumers for portable at-home cardiac monitoring via the Kardia app.
  • K1000 (InstantQT)
  • Kardia App Companion mobile application that captures, displays, and analyzes ECGs from Kardia hardware devices, provides AI interpretations, integrates with Apple Health and Google Fit, and includes the AskKardia AI assistant.
  • KardiaPro Enterprise platform for healthcare providers offering real-time heart rhythm analysis, population-level ECG insights, and clinician workflow integration.
  • KardiaStation Point-of-care ECG software for clinical settings, enabling in-clinic ECG capture and AI interpretation within healthcare provider workflows.
  • KardiaComplete (Virtual Center of Excellence) End-to-end remote cardiac care service that combines Kardia devices, AI interpretation, and clinician review to deliver a virtual Center of Excellence for cardiac monitoring and care, sold to payers, employers, and consultants on a PEPM basis.
  • KardiaCare Plus Subscription-based heart health membership for Kardia device users, providing expanded cardiac reporting, expert reviews, and access to KardiaComplete services.
  • API & SDK Solutions Developer-facing API and SDK offering that allows OEM partners and third-party developers to securely pull, analyze, and display ECG results using AliveCor's FDA-cleared AI algorithms, embed ECG technology into their own applications and devices, and leverage the 250M+ ECG database.

Companies that use AliveCor

Customer profile

Ideal customer profiles6 records

AliveCor technology and API

Technology

Technology focussed Yes

API detail

Has API
Yes
API docs
API detail

Core technology

AI maturity

App detail

Integration2 records

AI capability8 records

AliveCor partnerships and signals

Strategic signal

Recent moves6 records

Expansion highlights6 records

AliveCor competitors and assessment

Company assessment

Emerging players

  • HeartBeam: Early commercial-stage company developing a credit-card-sized 3D ECG device for at-home detection of heart attacks, with FDA-cleared synthesis software. Comparable emerging player in compact AI-ECG hardware and remote cardiac diagnostics.

Direct peers

  • Eko Health: AI-powered digital stethoscope and cardiac auscultation/ECG platform with FDA-cleared algorithms and an enterprise provider channel. Closely comparable to AliveCor on AI-ECG technology, clinical-grade hardware, and provider/payer sales motion.
  • Withings: Consumer health hardware maker offering ScanWatch and other devices with on-wrist ECG and cardiac monitoring integrated into a consumer health app. Directly comparable to AliveCor's KardiaMobile line in consumer-grade personal ECG hardware and consumer subscription model.
  • iRhythm Technologies: Public digital health company (Zio long-term continuous monitoring patch) offering AI-interpreted ambulatory cardiac monitoring with FDA-cleared algorithms. Directly comparable to AliveCor in AI-ECG interpretation, clinical cardiology customers, and reimbursement-driven go-to-market.

Broad incumbents

  • Philips (Cardiac Monitoring): Global medtech incumbent with a broad cardiac monitoring portfolio (including wearable ECG and inpatient telemetry) and AI-enabled cardiology analytics. Comparable to AliveCor at the clinical/enterprise tier where it competes for hospital and health system cardiac monitoring budgets.
  • GE Healthcare: Lead investor in AliveCor's Series F and a global medtech incumbent with cardiac diagnostics, patient monitoring, and AI imaging. A channel partner and investor, but also a broad incumbent whose cardiology portfolio overlaps AliveCor's clinical footprint at health systems.
  • Preventice Solutions (Boston Scientific): Acquired by Boston Scientific, Preventice offers BodyGuardian remote cardiac monitoring (MCOT) with AI-assisted arrhythmia detection. Comparable to AliveCor in remote cardiac monitoring services and enterprise/payer GTM.
  • Apple (Apple Watch ECG): Apple Watch ships a built-in single-lead ECG feature integrated with iOS/Apple Health, the largest direct consumer ECG distribution channel. A broad incumbent comparable to AliveCor on consumer ECG experience and a key antagonist in the recent AliveCor antitrust dispute.
  • Bardy Diagnostics (Baxter / Hillrom): Acquired by Hillrom (now Baxter), Bardy's CAM patch is a single-patient-use ambulatory ECG monitor with AI analysis. Comparable to AliveCor in patch/ambulatory AI-ECG and is now part of a large medtech portfolio competing for the same clinical accounts.

Others

  • Omron Healthcare: Investor and commercial partner in AliveCor (Series C and Series E participant) and a global leader in consumer and clinical cardiovascular monitoring (blood pressure, ECG). Comparable as a strategic ecosystem participant and channel partner, not a direct AI-ECG competitor.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

AliveCor social profiles

Digital presence

AliveCor compliance and trust

Trust signal

Compliance5 records

AliveCor financial estimates

Financial estimate

Revenue estimate

Valuation estimate

AliveCor leadership team

Management profile

Number of profiles

Profiles14 records

AliveCor subsidiaries and ownership

Company hierarchy

Subsidiaries4 records

AliveCor funding detail

Funding detail

Funding overview

Funding rounds8 records

Investors12 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

AliveCor M&A and investment

M&A and investment

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about AliveCor

What does AliveCor do?

AliveCor develops and sells AI-powered ECG hardware devices (consumer KardiaMobile line and clinical Kardia 12L) paired with FDA-cleared deep neural network algorithms (Kardia AI V2, KAI 12L, Corvair) that interpret cardiac data. The company also operates enterprise software (KardiaPro), a virtual Center of Excellence cardiac care service (KardiaComplete), a consumer subscription (KardiaCare Plus), and an API/SDK that enables OEMs to embed its ECG AI into third-party devices and applications.

Is AliveCor a public or private company?

AliveCor is a private company. It is classified as venture growth investor backed and is currently operating.

When was AliveCor founded?

AliveCor was founded in 2010. It employs 51 to 100 people.

Where is AliveCor based?

AliveCor is headquartered in Mountain View, United States, in the North America region.

Who are AliveCor's main competitors?

HeartBeam is listed as an emerging player. Direct peers are Eko Health, Withings and iRhythm Technologies. Broad incumbents are Philips (Cardiac Monitoring), GE Healthcare, Preventice Solutions (Boston Scientific), Apple (Apple Watch ECG) and Bardy Diagnostics (Baxter / Hillrom). Omron Healthcare is listed as an others.

Does AliveCor have an API?

Yes. AliveCor offers API and SDK Solutions enabling OEM partners and third-party developers to securely pull, analyze, and display ECG results using AliveCor's FDA-cleared AI algorithms. The APIs allow data storage and retrieval from the AliveCor cloud and are used by OEM partners to embed AliveCor's ECG technology into their own applications and devices. The SDK also enables third-party apps to leverage the 250M+ ECGs collected by AliveCor.

What industry is AliveCor in?

AliveCor's product category is Cardiac Diagnostic Devices and AI ECG Platform. Its primary akta.pro industry code is HLAHACAB, Cardiac Monitoring (ECG/Holter/Event/Patch, Loop Recorders), with a secondary code of HLALAGAB, Cardiology Telemedicine Platforms. Its NAICS code is 334510 and its SIC code is 3845.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
MedCity NewsMedCity Pivot Podcast: A Conversation With AliveCor’s Priya AbaniAliveCor CEO Priya Abani discussed the company's evolution from consumer wearables to a 12-lead ECG device for healthcare professionals. The device has FDA clearance for 39 cardiac conditions, and the company is integrating with GE Healthcare's Muse platform. Abani also mentioned a new Medicare-covered program, Kardia Access, expanding beyond arrhythmia.Longevity.TechnologyAliveCor launches $0 Medicare health programAliveCor launched KardiaACCESS, a Medicare-backed program offering free, clinician-guided cardio-kidney-metabolic care to eligible beneficiaries. The 10-year program is live in 48 states and covers two tracks for high-risk and established conditions. It aims to catch problems before hospitalization, though outcomes remain unclear.Longevity.TechnologyAliveCor launches KardiaACCESS for Medicare beneficiariesAliveCor launched KardiaACCESS, a Medicare-covered program for blood pressure, blood sugar, and cardio-kidney-metabolic health, available to eligible Part B beneficiaries with no out-of-pocket cost. The program, offered through Kardia Medical Group, is currently in 48 states with expansion to Arkansas and South Carolina planned.Longevity.TechnologyHandheld heart monitor doubles arrhythmia catchesA University of Rochester study of 350 adults found AliveCor's KardiaMobile 6L handheld ECG detected 52 arrhythmias versus 27 on Holter or patch monitors. The device caught 39 episodes missed by standard monitors, including atrial fibrillation, and 88% of users found it easy to use.pharmaphorumAliveCor and Omron create first combined ECG/blood pressure appAliveCor and Omron Healthcare partnered to integrate Omron blood pressure data into AliveCor's Kardia ECG app, creating the first combined ECG and blood pressure monitor app. The partnership aims to help patients monitor two vital heart health statistics in one place to reduce stroke risk.Medical Device and Diagnostic industryGoliath Defeats David: Court of Appeals Rules in Favor of Apple in AliveCor Patent SpatThe U.S. Court of Appeals ruled in favor of Apple, invalidating AliveCor's patents for heart-rate monitoring, averted an import ban on Apple Watches. AliveCor said it will explore appeals and continue innovating.Tracxn2026 Funding Rounds & List of InvestorsAliveCor's funding rounds from 2011 to 2022 are listed, including Series A through Series F and a conventional debt round. The rounds range from $345,520 to $5,644,410, with lead investors including Mayo Clinic Business Accelerator and Oxford Finance.Longevity.TechnologyKardiaMobile 6L outperforms traditional ECG monitors in new studyAliveCor announced that a prospective cohort study conducted by the University of Rochester and published in JACC Advances found its KardiaMobile 6L device outperformed traditional ambulatory ECG monitors in detecting clinically significant arrhythmias. The study of 350 patients showed the KM6L detected arrhythmias in 14.9% of participants compared to 7.7% for conventional monitors, capturing 39 episodes missed by standard devices. AliveCor claims this performance positions the device as an effective early adjunct in diagnostic pathways to improve symptom-rhythm correlation.The Manila TimesNew Study Demonstrates AliveCor’s KardiaMobile 6L Significantly Increases Arrhythmia Detection Beyond Traditional Ambulatory MonitoringAliveCor announced a prospective cohort study published in JACC Advances, conducted by researchers at the University of Rochester Clinical Cardiovascular Research Center, showing that 30-day use of the KardiaMobile 6L device nearly doubles arrhythmia detection yield versus traditional ambulatory monitoring. Of 350 patients, 66 (18.9%) had clinically significant arrhythmias, with 39 episodes (11.1%) captured only by the device.ForbesAI-ECG: A New Market For A Century-Old TestAI-ECG algorithms are rapidly gaining FDA clearance and hospital deployment despite clinical skepticism over evidence standards, with companies Anumana, Viz.ai, and AliveCor clearing regulatory hurdles for screening conditions like low ejection fraction, pulmonary hypertension, and cardiac amyloidosis on routine ECG tracings. Viz.ai reports diagnosis time for hypertrophic cardiomyopathy dropping from five years to five weeks at hundreds of US sites, while Medicare added reimbursement codes for AI-enabled ECG analysis in 2025. The core disagreement centers on whether evidence standards have been met for guideline adoption, with some clinicians requiring large RCTs demonstrating mortality benefit before accepting AI reads in clinical care.